Atherosclerosis and infection: Is the jury still not in?

Future Microbiology

Volumn 7, Issue 10, 2012, Pages 1217-1230

  Chatzidimitriou, Dimitrios ^a   Kirmizis, Dimitrios ^a   Gavriilaki, Eleni ^a   Chatzidimitriou, Maria ^b   Malisiovas, Nikolaos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ALEXANDER TECHNOLOGICAL EDUCATIONAL INSTITUTE OF THESSALONIKI   (Greece)

Author keywords

atherosclerosis; Chlamydophila pneumoniae; cytomegalovirus; Helicobacter pylori; infection; mechanisms; periodontal pathogen

Indexed keywords

CYCLOOXYGENASE 2; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRIN; HEAT SHOCK PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; MACROLIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P53; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; VASCULAR CELL ADHESION MOLECULE 1;

ARTERIAL WALL THICKNESS; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNITY; B LYMPHOCYTE; CAROTID ATHEROSCLEROSIS; CHLAMYDOPHILA PNEUMONIAE; CROSS REACTION; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFECT; ENTEROBACTER; ENTEROBACTER HORMAECHEI; FIBRIN DEPOSITION; GENE FREQUENCY; HEART INFARCTION; HELICOBACTER PYLORI; HUMAN; INFECTION; INFLAMMATION; NONHUMAN; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SMOOTH MUSCLE FIBER; SYSTEMATIC REVIEW (TOPIC); T LYMPHOCYTE; UPREGULATION;

ANIMALS; ATHEROSCLEROSIS; BACTERIAL INFECTIONS; DISEASE MODELS, ANIMAL; HUMANS; VIRUS DISEASES;

CHLAMYDOPHILA PNEUMONIAE; CYTOMEGALOVIRUS; HELICOBACTER PYLORI;

EID: 84867093708     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.12.87     Document Type: Review

References (200)

1. World Health Organization. The World Health Report 2008: Primary Health Care (Now More Than Ever). World Health Organization, Switzerland (2008).
2. Papagianni A, Kalovoulos M, Kirmizis D et al. Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic hemodialysis patients. Nephrol. Dial. Transplant. 18, 113-119 (2003).
3. Minick CR, Fabricant CG, Fabricant J, Litrenta MM. Atheroarteriosclerosis induced by infection with a herpesvirus. Am. J. Pathol. 96, 673-706 (1979).
4. Saikku P, Leinonen M, Mattila K et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 2(8618), 983-986 (1988).
5. Saikku P, Leinonen M, Tenkanen L et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann. Intern. Med. 116, 273-278 (1992).
6. Thom DH, Wang SP, Grayston JT et al. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arterioscler. Thromb. 11, 547-551 (1991).
7. Thom DH, Grayston JT, Siscovick DS, Wang SP, Weiss NS, Daling JR. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 268, 68-72 (1992).
8. Watson C, Alp NJ. Role of Chlamydia pneumoniae in atherosclerosis. Clin. Sci. (Lond.) 114, 509-531 (2008).
9. Bloemenkamp DG, Mali WP, Visseren FL, van der Graaf Y. Meta-analysis of seroepidemiologic studies of the relation between Chlamydia pneumoniae and atherosclerosis: does study design influence results? Am. Heart J. 145, 409-417 (2003).
10. Franceschi F, Niccoli G, Ferrante G et al. CagA antigen of Helicobacter pylori and coronary instability: insight from a clinico-pathological study and a meta-analysis of 4241 cases. Atherosclerosis 202(2), 535-542 (2009).
11. Niccoli G, Franceschi F, Cosentino N et al. Coronary atherosclerotic burden in patients with infection by CagA-positive strains of Helicobacter pylori. Coron. Artery Dis. 21(4), 217-221 (2010).
12. Diomedi M, Stanzione P, Sallustio F et al. Cytotoxin-associated gene-A-positive Helicobacter pylori strains infection increases the risk of recurrent atherosclerotic stroke. Helicobacter 13(6), 525-531 (2008).
13. Grahame-Clarke C. Human cytomegalovirus, endothelial function and atherosclerosis. Herpes 12(2), 42-45 (2005).
14. Danesh J. Coronary heart disease, Helicobacter pylori, dental disease, Chlamydia pneumoniae, and cytomegalovirus: metaanalyses of prospective studies. Am. Heart J. 138(5 Pt 2), S434-S437 (1999).
15. Grahame-Clarke C, Chan NN. Human cytomegalovirus seropositivity is associated with impaired vascular function. Circulation 108(6), 678-683 (2003).
16. Roberts ET, Haan MN, Dowd JB, Aiello AE. Cytomegalovirus antibody levels, inflammation, and mortality among elderly Latinos over 9 years of follow-up. Am. J. Epidemiol. 172(4), 363-371 (2010).
17. Betjes MG, Litjens NH, Zietse R. Seropositivity for cytomegalovirus in patients with end-stage renal disease is strongly associated with atherosclerotic disease. Nephrol. Dial. Transplant. 22(11), 3298-3303 (2007).
18. Mattila KJ, Nieminen MS, Valtonen VV et al. Association between dental health and acute myocardial infarction. BMJ 298(6676), 779-781 (1989).
19. Syrjänen J, Peltola J, Valtonen V et al. Dental infections in association with cerebral infarction in young and middle-aged men. J. Intern. Med. 225(3), 179-184 (1989).
20. Bahekar AA, Singh S, Saha S, Molnar J, Arora R. The prevalence and incidence of coronary heart disease is significantly increased in periodontitis: a meta-analysis. Am. Heart J. 154(5), 830-837 (2007).
21. Humphrey LL, Fu R, Buckley DI, Freeman M, Helfand M. Periodontal disease and coronary heart disease incidence: a systematic review and meta-analysis. J. Gen. Intern. Med. 23(12), 2079-2086 (2008).
22. Blaizot A, Vergnes JN, Nuwwareh S, Amar J, Sixou M. Periodontal diseases and cardiovascular events: meta-analysis of observational studies. Int. Dent. J. 59(4), 197-209 (2009).
23. Jimenez M, Krall EA, Garcia RI, Vokonas PS, Dietrich T. Periodontitis and incidence of cerebrovascular disease in men. Ann. Neurol. 66(4), 505-512 (2009).
24. Beck JD, Eke P, Lin D et al. Associations between IgG antibody to oral organisms and carotid intima-medial thickness in community-dwelling adults. Atherosclerosis 183(2), 342-348 (2005).
25. Danesh J, Whincup P, Walker M et al. Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. BMJ 321, 208-213 (2000).
26. Danesh J, Whincup P, Lewington S et al. Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and meta-analysis. Eur. Heart J. 23(5), 371-375 (2002).
27. Schimke K, Chubb SA, Davis WA, Davis TM. Helicobacter pylori cytotoxin-associated gene-A antibodies do not predict complications or death in Type 2 diabetes: the Fremantle Diabetes Study. Atherosclerosis 212(1), 321-326 (2010).
28. Ieven MM, Hoymans VY. Involvement of Chlamydia pneumoniae in atherosclerosis: more evidence for lack of evidence. J. Clin. Microbiol. 43, 19-24 (2005).
29. Apfalter P, Loidl M, Nadrchal R et al. Isolation and continuous growth of Chlamydia pneumoniae from arterectomy specimens. Eur. J. Clin. Microbiol. Infect. Dis. 19(4), 305-308 (2000).
30. Smieja M, Mahony J, Petrich A, Boman J, Chernesky M. Association of circulating Chlamydia pneumoniae DNA with cardiovascular disease: a systematic review. BMC Infect. Dis. 2, 21 (2002).
31. Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 288(21), 2724-2731 (2002).
32. Ameriso SF, Fridman EA, Leiguarda RC, Sevlever GE. Detection of Helicobacter pylori in human carotid atherosclerotic plaques. Stroke 32(2), 385-391 (2001).
33. Kaplan M, Yavuz SS, Cinar B et al. Detection of Chlamydia pneumoniae and Helicobacter pylori in atherosclerotic plaques of carotid artery by polymerase chain reaction. Int. J. Infect. Dis. 10(2), 116-123 (2006).
34. Fong IW. Emerging relations between infectious diseases and coronary artery disease and atherosclerosis. CMAJ 163(1), 49-56 (2000).
35. Gredmark S, Jonasson L, Van Gosliga D, Ernerudh J, Söderberg- Nauclér C. Active cytomegalovirus replication in patients with coronary disease. Scand. Cardiovasc. J. 41(4), 230-234 (2007).
36. Haraszthy VI, Zambon JJ, Trevisan M, Zeid M, Genco RJ. Identification of periodontal pathogens in atheromatous plaques. J. Periodontol. 71(10), 1554-1560 (2000).
37. Cavrini F, Sambri V, Moter A et al. Molecular detection of Treponema denticola and P. gingivalis in carotid and aortic atheromatous plaques by FISH: report of two cases. J. Med. Microbiol. 54(Pt 1), 93-96 (2005).
38. Kozarov EV, Dorn BR, Shelburne CE, Dunn WA Jr, Progulske-Fox A. Human atherosclerotic plaque contains viable invasive Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis. Arterioscler. Thromb. Vasc. Biol. 25(3), E17-E18 (2005).
39. Blessing E, Campbell LA, Rosenfeld ME, Chough N, Kuo CC. Chlamydia pneumoniae infection accelerates hyperlipidemia induced atherosclerotic lesion development in C57BL/6J mice. Atherosclerosis 158(1), 13-17 (2001).
40. Ezzahiri R, Stassen FR, Kurvers HA et al. Chlamydia pneumoniae infection induces an unstable atherosclerotic plaque phenotype in LDL-receptor, ApoE double knockout mice. Eur. J. Vasc. Endovasc. Surg. 26(1), 88-95 (2003).
41. Fong IW, Chiu B, Viira E, Fong MW, Jang D, Mahony J. Rabbit model for Chlamydia pneumoniae infection. J. Clin. Microbiol. 35(1), 48-52 (1997).
42. Span AH, Van Boven CP, Bruggeman CA. The effect of cytomegalovirus infection on the adherence of polymorphonuclear leucocytes to endothelial cells. Eur. J. Clin. Invest. 19, 542-548 (1989).
43. Naghavi M, Wyde P, Litovsky S et al. Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoproteins E-deficient mice. Circulation 107, 762-768 (2003).
44. Burnett MS, Gaydos CA, Madico GE et al. Atherosclerosis in apoE knockout mice infected with multiple pathogens. J. Infect. Dis. 183, 226-231 (2001).
45. Ezzahiri R, Nelissen-Vrancken HJ, Kurvers HA et al. Chlamydophila pneumoniae (Chlamydia pneumoniae) accelerates the formation of complex atherosclerotic lesions in apo E3-Leiden mice. Cardiovasc. Res. 56, 269-276 (2002).
46. Vliegen I, Duijvestijn A, Grauls G, Herngreen S, Bruggeman C, Stassen F. Cytomegalovirus infection aggravates atherogenesis in apoE knockout mice by both local and systemic immune activation. Microbes Infect. 6(1), 17-24 (2004).
47. Wang Q, Zhou X, Huang D. Role for Porphyromonas gingivalis in the progression of atherosclerosis. Med. Hypotheses 72(1), 71-73 (2009).
48. Tabeta K, Yamazaki K, Hotokezaka H, Yoshie H, Hara K. Elevated humoral immune response to heat shock protein 60 (HSP60) family in periodontitis patients. Clin. Exp. Immunol. 120, 285-293 (2000).
49. Ford PJ, Gemmell E, Hamlet SM et al. Cross-reactivity of GroEL antibodies with human heat shock protein 60 and quantification of pathogens in atherosclerosis. Oral Microbiol. Immunol. 20(5), 296-302 (2005).
50. Ford P, Gemmell E, Walker P, West M, Cullinan M, Seymour G. Characterization of heat shock protein-specific T cells in atherosclerosis. Clin. Diagn. Lab. Immunol. 12(2), 259-267 (2005).
51. Yamazaki K, Ohsawa Y, Tabeta K et al. Accumulation of human heat shock protein 60-reactive T cells in the gingival tissues of periodontitis patients. Infect. Immun. 70, 2492-2501 (2002).
52. Yamazaki K, Ohsawa Y, Itoh H et al. T-cell clonality to Porphyromonas gingivalis and human heat shock protein 60s in patients with atherosclerosis and periodontitis. Oral Microbiol. Immunol. 19(3), 160-167 (2004).
53. Amar S, Wu SC, Madan M. Is Porphyromonas gingivalis cell invasion required for atherogenesis? Pharmacotherapeutic implications. J. Immunol. 182(3), 1584-1592 (2009).
54. Joshipura KJ, Rimm EB, Douglass CW, Trichopoulos D, Ascherio A, Willett WC. Poor oral health and coronary heart disease. J. Dent. Res. 75, 1631-1636 (1996).
55. Hujoel PP, Drangsholt M, Spiekerman C, DeRouen TA. Periodontal disease and coronary heart disease risk. JAMA 284, 1406-1410 (2000).
56. Lokhart PB, Bolger AF, Papapanou P et al. Periodontal disease and atherosclerotic vascular disease: does the evidence support an independent association? A scientific statement from the American Heart Association. Circulation 125, 2520-2544 (2012).
57. Schanen C, Nasri D, Bourlet T et al. Enterovirus in arteriosclerosis: a pilot study. J. Clin. Virol. 39(2), 106-112 (2007).
58. Rafferty B, Dolgilevich S, Kalachikov S et al. Cultivation of Enterobacter hormaechei from human atherosclerotic tissue. J. Atheroscler. Thromb. 18, 72-81 (2011).
59. Chatzidimitriou D, Exindari M, Gavriilaki E et al. Absence of human bocavirus in atherosclerotic plaques of carotid arteries by real-time polymerase chain reaction. Scand. J. Infect. Dis. 42(8), 623-625 (2010).
60. Aslam F, Alam M, Lakkis NM. Hepatitis C and carotid atherosclerosis: a retrospective analysis. Atherosclerosis 209(2), 340-343 (2010).
61. Boddi M, Abbate R, Chellini B et al. Hepatitis C virus RNA localization in human carotid plaques. J. Clin. Virol. 47(1), 72-75 (2010).
62. Currier JS, Lundgren JD, Carr A et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 118, E29-E35 (2008).
63. Currier JS, Taylor A, Boyd et al. Coronary heart disease in HIV-infected individuals J. Acquir. Immune Defic. Syndr. 33, 506-512 (2003).
64. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J. Acquir. Immune Defic. Syndr. 30, 471-477 (2002).
65. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J. Clin. Endocrinol. Metab. 92, 2506-2512 (2007).
66. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction J. Acquir. Immune Defic. Syndr. 51, 268-273 (2009).
67. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J. Acquir. Immune Defic. Syndr. 30(5), 471-477 (2002).
68. Hakeem A, Bhatti S, Cilingiroglu M. The spectrum of atherosclerotic coronary artery disease in HIV patients. Curr. Atheroscler. Rep. 12(2), 119-124 (2010).
69. Seaberg EC, Benning L, Sharrett AR et al. Association between human immunodeficiency virus infection and stiffness of the common carotid artery. Stroke 41(10), 2163-2170 (2010).
70. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N. Engl. J. Med. 348(14), 1322-1332 (2003).
71. Madjid M, Naghavi M, Litovsky S, Casscells SW. Influenza and cardiovascular disease: a new opportunity for prevention and the need for further studies. Circulation 108(22), 2730-2736 (2003).
72. Gurfinkel EP, Leon de la Fuente R, Mendiz O, Mautner B. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) study. Eur. Heart J. 25(1), 25-31 (2004).
73. Davis MM, Taubert K, Benin AL et al. Influenza vaccination as secondary prevention for cardiovascular disease. A science advisory from the American Heart Association/ American College of Cardiology. Circulation 114, 1549-1553 (2006).
74. Haidari M, Wyde PR, Litovsky S et al. Influenza virus directly infects, inflames, and resides in the arteries of atherosclerotic and normal mice. Atherosclerosis 208(1), 90-96 (2010).
75. Maciejewski JP, Bruening EE, Donahue RE, Mocarski ES, Young NS, St Jeor SC. Infection of hematopoietic progenitor cells by human cytomegalovirus. Blood 80, 170-178 (1992).
76. Epstein SE, Zhou YF, Zhu J. Infection and atherosclerosis: emerging mechanistic paradigms. Circulation 100, E20-E28 (1999).
77. Kozarov E, Sweier D, Shelburne C, Progulske-Fox A, Lopatin D. Detection of bacterial DNA in atheromatous plaques by quantitative PCR. Microbes Infect. 8, 687-693 (2006).
78. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. 91, 281-291 (2002).
79. Nazmi A, Diez-Roux AV, Jenny NS, Tsai MY, Szklo M, Aiello AE. The influence of persistent pathogens on circulating levels of inflammatory markers: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis. BMC Public Health 10, 706 (2010).
80. Ibanez CE, Schrier R, Ghazal P, Wiley C, Nelson JA. Human cytomegalovirus productively infects primary differentiated macrophages. J. Virol. 65, 6581-6588 (1991).
81. Grundy JE, Downes KL. Up-regulation of LFA-3 and ICAM-1 on the surface of fibroblasts infected with cytomegalovirus. Immunology 78, 405-412 (1993).
82. Span AH, Mullers W, Miltenburg AM, Bruggeman CA. Cytomegalovirus induced PMN adherence in relation to an ELAM-1 antigen present on infected endothelial cell monolayers. Immunology 72, 355-360 (1991).
83. Speir E, Yu ZX, Ferrans VJ, Huang ES, Epstein SE. Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by cyclooxygenase-2 in coronary artery smooth muscle cells. Circ. Res. 83, 210-216 (1998).
84. Kaukoranta-Tolvanen SS, Ronni T, Leinonen M, Saikku P, Laitinen K. Expression of adhesion molecules on endothelial cells stimulated by Chlamydia pneumoniae. Microb. Pathog. 21, 407-411 (1996).
85. Coombes BK, Mahony JB. Chlamydia pneumoniae infection of human endothelial cells induces proliferation of smooth muscle cells via an endothelial cell-derived soluble factor(s). Infect. Immun. 67, 2909-2915 (1999).
86. Dechend R, Maass M, Gieffers J et al. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis. Circulation 100, 1369-1373 (1999).
87. Zhou YF, Guetta E, Yu ZX, Finkel T, Epstein SE. Human cytomegalovirus increases modified low density lipoprotein uptake and scavenger receptor mRNA expression in vascular smooth muscle cells. J. Clin. Invest. 98, 2129-2138 (1996).
88. Kalayoglu MV, Byrne GI. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J. Infect. Dis. 177, 725-729 (1998).
89. Deniset JF, Cheung PK, Dibrov E, Lee K, Steigerwald S, Pierce GN. Chlamydophila pneumoniae infection leads to smooth muscle cell proliferation and thickening in the coronary artery without contributions from a host immune response. Am. J. Pathol. 176(2), 1028-1037 (2010).
90. Mei CL, He P, Cheng B, Liu W, Wang YF, Wan JJ. Chlamydia pneumoniae induces macrophage-derived foam cell formation via PPAR alpha and PPAR gamma-dependent pathways. Cell. Biol. Int. 33(3), 301-308 (2009).
91. He P, Mei C, Cheng B, Liu W, Wang Y, Wan J. Chlamydia pneumoniae induces macrophage-derived foam cell formation by up-regulating acyl-coenzyme A: cholesterol acyltransferase 1. Microbes Infect. 11(2), 157-163 (2009).
92. Faure E, Equils O, Sieling PA et al. Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells: differential expression of TLR-4 and TLR-2 in endothelial cells. J. Biol. Chem. 275, 11058-11063 (2000).
93. Erkkila L, Laitinen K, Haasio K et al. Heat shock protein 60 autoimmunity and early lipid lesions in cholesterol-fed C57BL/6JBom mice during Chlamydia pneumoniae infection. Atherosclerosis 177, 321-328 (2004).
94. Corcoran PA, Atherton JC, Kerrigan SW et al. The effect of different strains of Helicobacter pylori on platelet aggregation. Can. J. Gastroenterol. 21, 367-370 (2007).
95. Visser MR, Tracy PB, Vercellotti GM, Goodman JL, White JG, Jacob HS. Enhanced thrombin generation and platelet binding on herpes simplex virus-infected endothelium. Proc. Natl Acad. Sci. USA 85, 8227-8230 (1988).
96. Key NS, Vercellotti GM, Winkelmann JC et al. Infection of vascular endothelial cells with herpes simplex virus enhances tissue factor activity and reduces thrombomodulin expression. Proc. Natl Acad. Sci. USA 87, 7095-7099 (1990).
97. Etingin OR, Silverstein RL, Friedman HM, Hajjar DP. Viral activation of the coagulation cascade: molecular interactions at the surface of infected endothelial cells. Cell 61, 657-662 (1990).
98. van Dam-Mieras MC, Muller AD, van Hinsbergh VW, Mullers WJ, Bomans PH, Bruggeman CA. The procoagulant response of cytomegalovirus infected endothelial cells. Thromb. Haemost. 68, 364-370 (1992).
99. Kaukoranta-Tolvanen SS, Ronni T, Leinonen M, Saikku P, Laitinen K. Expression of adhesion molecules on endothelial cells stimulated by Chlamydia pneumoniae. Microb. Pathog. 21, 407-411 (1996).
100. Dechend R, Maass M, Gieffers J et al. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis. Circulation 100, 1369-1373 (1999).
101. Iwai T. Periodontal bacteremia and various vascular diseases. J. Periodontal. Res. 44(6), 689-694 (2009).
102. Chou HH, Yumoto H, Davey M et al. Porphyromonas gingivalis fimbria-dependent activation of inflammatory genes in human aortic endothelial cells. Infect. Immun. 73, 5367-5378 (2005).
103. Niu J, Kolattukudy PE. Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications. Clin. Sci. (Lond.) 117, 95-109 (2009).
104. Desta T, Graves DT. Fibroblast apoptosis induced by Porphyromonas gingivalis is stimulated by a gingipain and caspaseindependent pathway that involves apoptosisinducing factor. Cell. Microbiol. 9, 2667-2675 (2007).
105. Inaba H, Hokamura K, Nakano K et al. Upregulation of S100 calcium-binding protein A9 is required for induction of smooth muscle cell proliferation by a periodontal pathogen. FEBS Lett. 583, 128-134 (2009).
106. Kebschull M, Demmer RT, Papapanou PN. 'Gum bug, leave my heart alone!' -epidemiologic and mechanistic evidence linking periodontal infections and atherosclerosis. J. Dent. Res. 89(9), 879-902 (2010).
107. Carallo C, Fortunato L, de Franceschi MS. Periodontal disease and carotid atherosclerosis: are hemodynamic forces a link? Atherosclerosis 213(1), 263-267 (2010).
108. Zhou YF, Shou M, Guetta E et al. Cytomegalovirus infection of rats increases the neointimal response to vascular injury without consistent evidence of direct infection of the vascular wall. Circulation 100, 1569-1575 (1999).
109. Vliegen I, Herngreen SB, Grauls GE, Bruggeman CA, Stassen FR. Mouse cytomegalovirus antigenic immune stimulation is sufficient to aggravate atherosclerosis in hypercholesterolemic mice. Atherosclerosis 181, 39-44 (2005).
110. Kirmizis D, Efstratiadis G, Economidou D, Diza-Mataftsi E, Leontsini M, Memmos D. MPGN secondary to Lyme disease. Am. J. Kidney Dis. 43(3), 544-551 (2004).
111. Blasi C. The autoimmune origin of atherosclerosis. Atherosclerosis 201(1), 17-32 (2008).
112. Ibanez CE, Schrier R, Ghazal P, Wiley C, Nelson JA. Human cytomegalovirus productively infects primary differentiated macrophages. J. Virol. 65, 6581-6588 (1991).
113. Guetta E, Guetta V, Shibutani T, Epstein SE. Monocytes harboring cytomegalovirus: interactions with endothelial cells, smooth muscle cells, and oxidized low-density lipoprotein: possible mechanisms for activating virus delivered by monocytes to sites of vascular injury. Circ. Res. 81, 8-16 (1997).
114. Gurer C, Cimarelli A, Luban J. Specific incorporation of heat shock protein 70 family members into primate lentiviral virions. J. Virol. 76, 4666-4670 (2002).
115. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 98, 300-307 (1998).
116. Xu Q, Wick G. The role of heat shock proteins in protection and pathophysiology of the arterial wall. Mol. Med. Today 2, 372-379 (1996).
117. Zhu J, Quyyumi AA, Rott D et al. Antibodies to human heat-shock protein 60 are associated with the presence and severity of coronary artery disease: evidence for an autoimmune component of atherogenesis. Circulation 103, 1071-1075 (2001).
118. Olivares-Zavaleta N, Carmody A, Messer R, Whitmire WM, Caldwell HD. Chlamydia pneumoniae inhibits activated human T lymphocyte proliferation by the induction of apoptotic and pyroptotic pathways. J. Immunol. 186(12), 7120-7126 (2011).
119. Beatty WL, Morrison RP, Byrne GI. Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol. Rev. 58, 686-699 (1994).
120. Krams R, Segers D, Mousavi Gourabi B et al. Inflammation and atherosclerosis: mechanisms underlying vulnerable plaque. J. Interv. Cardiol. 16(2), 107-113 (2003).
121. Mayr M, Metzler B, Kiechl S et al. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation 99, 1560-1566 (1999).
122. Zhu J, Katz RJ, Quyyumi AA et al. Association of serum antibodies to heat-shock protein 65 with coronary calcification levels: suggestion of pathogen-triggered autoimmunity in early atherosclerosis. Circulation 109, 36-41 (2004).
123. Speir E, Modali R, Huang ES et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 265, 391-394 (1994).
124. Tanaka K, Zou JP, Takeda K et al. Effects of human cytomegalovirus immediate-early proteins on p53-mediated apoptosis in coronary artery smooth muscle cells. Circulation 99, 1656-1659 (1999).
125. Zhou YF, Guetta E, Yu ZX, Finkel T, Epstein SE. Human cytomegalovirus increases modified low density lipoprotein uptake and scavenger receptor mRNA expression in vascular smooth muscle cells. J. Clin. Invest. 98, 2129-2138 (1996).
126. Zhou YF, Yu ZX, Wanishsawad C, Shou M, Epstein SE. The immediate early gene products of human cytomegalovirus increase vascular smooth muscle cell migration, proliferation, and expression of PDGF beta-receptor. Biochem. Biophys. Res. Commun. 256, 608-613 (1999).
127. Madan M, Amar S. Toll-like receptor-2 mediates diet and/or pathogen associated atherosclerosis: proteomic findings. PLoS One 3(9), e3204 (2008).
128. Muzio M, Natoli G, Saccani S, Levrero M, Mantovani A. The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J. Exp. Med. 187, 2097-2101 (1998).
129. Balistreri CR, Candore G, Listi F et al. Role of TLR4 polymorphisms in inflammatory responses: implications for unsuccessful aging. Ann. NY Acad. Sci. 1119, 203-207 (2007).
130. Candore G, Aquino A, Balistreri CR et al. Inflammation, longevity, and cardiovascular diseases: role of polymorphisms of TLR4. Ann. NY Acad. Sci. 1067, 282-287 (2006).
131. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of Toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105, 1158-1161 (2002).
132. Michelsen KS, Wong MH, Shah PK et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl Acad. Sci. USA 101, 10679-10684 (2004).
133. Madan M, Bishayi B, Hoge M, Amar S. Atheroprotective role of interleukin-6 in diet-and/or pathogen-associated atherosclerosis using an apoE heterozygote murine model. Atherosclerosis 197(2), 504-514 (2008).
134. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. J. Clin. Invest. 115, 3149-3156 (2005).
135. Stassen FR, Vainas T, Bruggeman CA. Infection and atherosclerosis: an alternative view on an outdated hypothesis. Pharmacol. Rep. 60, 85-92 (2008).
136. Zhu J, Quyyumi AA, Norman JE, Csako G, Epstein SE. Cytomegalovirus in the pathogenesis of atherosclerosis: the role of inflammation as reflected by elevated C-reactive protein levels. J. Am. Coll. Cardiol. 34, 1738-1743 (1999).
137. Zhu J, Shearer GM, Norman JE et al. Host response to cytomegalovirus infection as a determinant of susceptibility to coronary artery disease: sex-based differences in inflammation and type of immune response. Circulation 102, 2491-2496 (2000).
138. Sander K, Horn CS, Briesenick C. Highsensitivity C-reactive protein is independently associated with early carotid artery progression in women but not in men: the INVADE study. Stroke 38(11), 2881-2886 (2007).
139. Momiyama Y, Hirano R, Taniguchi H, Nakamura H, Ohsuzu F. Effects of interleukin-1 gene polymorphisms on the development of coronary artery disease associated with Chlamydia pneumoniae infection. J. Am. Coll. Cardiol. 38, 712-717 (2001).
140. Poikonen K, Lajunen T, Silvennoinen-Kassinen S, Paldanius M, Leinonen M, Saikku P. Susceptibility of human monocytemacrophages to Chlamydia pneumoniae infection in vitro is highly variable and associated with levels of soluble CD14 and C. pneumoniae IgA and human HSP-IgG antibodies in serum. Scand. J. Immunol. 67(3), 279-284 (2008).
141. Ameziane N, Beillat T, Verpillat P et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler. Thromb. Vasc. Biol. 23, E61-E64 (2003).
142. Boekholdt SM, Agema WRP, Peters RJG et al. Variants of Toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 107, 2416-2421 (2003).
143. Holloway JW, Yang IA, Ye S. Variation in the Toll-like receptor 4 gene and susceptibility to myocardial infarction. Pharmacogenet. Genomics 15, 15-21 (2005).
144. Behle JH, Sedaghatfar MH, Demmer RT. Heterogeneity of systemic inflammatory responses to periodontal therapy. J. Clin. Periodontol. 36(4), 287-294 (2009).
145. Anderson JL, Muhlestein JB. Antibiotic trials for coronary heart disease. Tex. Heart Inst. J. 31, 33-38 (2004).
146. Etminan M, Carleton B, Delaney JA, Padwal R. Macrolide therapy for Chlamydia pneumoniae in the secondary prevention of coronary artery disease: a meta-analysis of randomized controlled trials. Pharmacotherapy 24, 338-343 (2004).
147. Andraws R, Berger JS, Brown DL. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA 293, 2641-2647 (2005).
148. Gluud C, Als-Nielsen B, Damgaard M et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology 111, 280-287 (2008).
149. Stone AF, Mendall MA, Kaski JC et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 106, 1219-1223 (2002).
150. Elizalde JI, Pérez-Pujol S, Heras M et al. Effects of Helicobacter pylori eradication on platelet activation and disease recurrence in patients with acute coronary syndromes. Helicobacter 9(6), 681-689 (2004).
151. Koizumi Y, Kurita-Ochiai T, Oguchi S, Yamamoto M. Nasal immunization with Porphyromonas gingivalis outer membrane protein decreases P. gingivalis-induced atherosclerosis and inflammation in spontaneously hyperlipidemic mice. Infect. Immun. 76(7), 2958-2965 (2008).
152. Madan M, Bishayi B, Hoge M, Messas E, Amar S. Doxycycline affects diet-and bacteria-associated atherosclerosis in an apoE heterozygote murine model: cytokine profiling implications. Atherosclerosis 190(1), 62-72 (2007).
153. Asikainen SE. Periodontal bacteria and cardiovascular problems. Future Microbiol. 4, 495-498 (2009).
154. Seinost G, Wimmer G, Skerget M et al. Periodontal treatment improves endothelial dysfunction in patients with severe periodontitis. Am. Heart J. 149(6), 1050-1054 (2005).
155. Elter JR, Hinderliter AL, Offenbacher S et al. The effects of periodontal therapy on vascular endothelial function: a pilot trial. Am. Heart J. 151(1), 47 (2006).
156. Tonetti MS, D'Aiuto F, Nibali L et al. Treatment of periodontitis and endothelial function. N. Engl. J. Med. 356(9), 911-920 (2007).
157. Piconi S, Trabattoni D, Luraghi C et al. Treatment of periodontal disease results in improvements in endothelial dysfunction and reduction of the carotid intima-media thickness. FASEB J. 3(4), 1196-1204 (2009).
158. Offenbacher S, Beck JD, Moss K et al. Results from the Periodontitis and Vascular Events (PAVE) study: a pilot multicentered, randomized, controlled trial to study effects of periodontal therapy in a secondary prevention model of cardiovascular disease. J. Periodontol. 80(2), 190-201 (2009).
159. Kirmizis D, Chatzidimitriou D. Pleiotropic vasoprotective effects of statins: the chicken or the egg? Drug Des. Devel. Ther. 3, 191-204 (2009).
160. Kirmizis D, Chatzidimitriou D. Antiatherogenic effects of vitamin E: the search for the holy grail. Vasc. Health Risk Manag. 5, 767-774 (2009).
161. Gilbert A, Lion G. Artérites infectieuses expérimentales. CR Séances Soc. Biol. Fil. 41, 583-584 (1889).
162. Ilbäck NG, Mohammed A, Fohlman J, Friman G. Cardiovascular lipid accumulation with coxsackie B virus infection in mice. Am. J. Pathol. 136(1), 159-167 (1990).
163. Nicholls AC, Thomas M. Coxsackie virus infection in acute myocardial infarction. Lancet 1(8017), 883-884 (1977).
164. Griffiths PD, Hannington G, Booth JC. Coxsackie B virus infections and myocardial infarction. Results from a prospective, epidemiologically controlled study. Lancet 1(8183), 1387-1389 (1980).
165. Fabricant CG, Krook L, Gillespie JH. Virus-induced cholesterol crystals. Science 181(99), 566-567 (1973).
166. Melnick JL, Adam E, Debakey ME. Cytomegalovirus and atherosclerosis. Eur. Heart J. 14(Suppl. K), S30-S38 (1993).
167. Heiss G, Sharrett AR, Barnes R, Chambless LE, Szklo M, Alzola C. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am. J. Epidemiol. 134, 250-256 (1991).
168. Nieto FJ, Adam E, Sorlie P et al. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation 94, 922-927 (1996).
169. Chiu B, Viira E, Tucker W, Fong IW. Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. Circulation 96, 2144-2148 (1997).
170. Hendrix MG, Salimans MM, van Boven CP, Bruggeman CA. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am. J. Pathol. 136, 23-28 (1990).
171. Hendrix MG, Dormans PH, Kitslaar P, Bosman F, Bruggeman CA. The presence of cytomegalovirus nucleic acids in arterial walls of atherosclerotic and nonatherosclerotic patients. Am. J. Pathol. 134, 1151-1157 (1989).
172. Hendrix MG, Daemen M, Bruggeman CA. Cytomegalovirus nucleic acid distribution within the human vascular tree. Am. J. Pathol. 138, 563-567 (1991).
173. Kotronias D, Kapranos N. Herpes simplex virus as a determinant risk factor for coronary artery atherosclerosis and myocardial infarction. In Vivo 19, 351-357 (2005).
174. Benditt EP, Barrett T, McDougall JK. Viruses in the etiology of atherosclerosis. Proc. Natl Acad. Sci. USA 80, 6386-6389 (1983).
175. Muhlestein JB, Hammond EH, Carlquist JF et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J. Am. Coll. Cardiol. 27, 1555-1561 (1996).
176. Chiu B. Multiple infections in carotid atherosclerotic plaques. Am. Heart J. 138, S534-S536 (1999).
177. Ott SJ, El Mokhtari NE, Musfeldt M et al. Detection of diverse bacterial signatures in atherosclerotic lesions of patients with coronary heart disease. Circulation 113, 929-937 (2006).
178. Berger M, Schroder B, Daeschlein G et al. Chlamydia pneumoniae DNA in non-coronary atherosclerotic plaques and circulating leukocytes. J. Lab. Clin. Med. 136, 194-200 (2000).
179. Farsak B, Yildirir A, Akyön Y et al. Detection of Chlamydia pneumoniae and Helicobacter pylori DNA in human atherosclerotic plaques by PCR. J. Clin. Microbiol. 38, 4408-4411 (2000).
180. Musiani M, Zerbini ML, Muscari A et al. Antibody patterns against cytomegalovirus and Epstein-Barr virus in human atherosclerosis. Microbiologica 13(1), 35-41 (1990).
181. Csonka E, Bayer PI, Büki K, Várady G. Influence of the measles virus on the proliferation and protein synthesis of aortic endothelial and smooth muscle cells. Acta Microbiol. Hung. 37(2), 193-200 (1990).
182. Mendall MA, Goggin PM, Molineaux N et al. Relation of Helicobacter pylori infection and coronary heart disease. Br. Heart J. 71(5), 437-439 (1994).
183. Constans J, Marchand JM, Conri C et al. Asymptomatic atherosclerosis in HIVpatients: a case control ultrasound study. Ann. Med. 27(6), 683-685 (1995).
184. Lovey PY, Morabia A, Bleed D, Péter O, Dupuis G, Petite J. Long term vascular complications of Coxiella burnetii infection in Switzerland: cohort study. BMJ 319(7205), 284-286 (1999).
185. Chiu B. Multiple infections in carotid atherosclerotic plaques. Am. Heart J. 138(5 Pt 2), S534-S536 (1999).
186. Zhu J, Quyyumi AA, Norman JE, Costello R, Csako G, Epstein SE. The possible role of hepatitis A virus in the pathogenesis of atherosclerosis. J. Infect. Dis. 182, 1583-1587 (2000).
187. Ishizaka N, Ishizaka Y, Takahashi E et al. Increased prevalence of carotid atherosclerosis in hepatitis B virus carriers. Circulation 105, 1028-1030 (2002).
188. Ishizaka N, Ishizaka Y, Takahashi E et al. Association between hepatitis C seropositivity, carotid artery plaque and intima-media thickening. Lancet 359, 133-135 (2002).
189. Kuo HK, Fujise K. Human papillomavirus and cardiovascular disease among U.S. women in the National Health and Nutrition Examination Survey, 2003 to 2006. J. Am. Coll. Cardiol. 58, 2001-2006 (2011).
190. Muhlestein JB, Anderson JL, Carlquist JF et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 102, 1755-1760 (2000).
191. O'Connor CM, Dunne MW, Pfeffer MA et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. Investigators in the WIZARD Study. JAMA 290, 1459-1466 (2003).
192. Grayston JT, Kronmal RA, Jackson LA et al. Azithromycin for the secondary prevention of coronary events. N. Engl. J. Med. 352, 1637-1645 (2005).
193. Gluud C, Als-Nielsen B, Damgaard M et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology 111, 280-287 (2008).
194. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS study. Eur. Heart J. 20, 121-127 (1999).
195. Sinisalo J, Mattila K, Valtonen V et al. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-Q-wave coronary syndrome. Circulation 105, 1555-1560 (2002).
196. Zahn R, Schneider S, Frilling B et al. Antibiotic therapy after acute myocardial infarction: a prospective randomized study. Circulation 107, 1253-1259 (2003).
197. Cercek B, Shah PK, Noc M et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet 361(9360), 809-813 (2003).
198. Cannon CP, Braunwald E, McCabe CH et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy -Thrombolysis in Myocardial Infarction 22 Investigators. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N. Engl. J. Med. 352(16), 1646-1654 (2005).
199. Neumann F, Kastrati A, Miethke T. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet 357, 2085-2089 (2001).
200. Sander D, Winbeck K, Klingelhöfer J et al. Reduced progression of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity. Circulation 106, 2428-2433 (2002).